PACE-CME

BET inhibition in renal and cardiovascular disease: What is the clinical roadmap?

BET inhibition in renal and cardiovascular disease What is the clinical roadmap
RestartResume
10' education - June 5, 2017 - ERA-EDTA, Madrid Spain - Kamyar Kalantar-Zade, MD UC Irvine School of Medicine Irvine, Ca, USA
  • Overview

    Kamyar Kalantar-Zade, MD shows the data based on which alkaline phosphatase is emerging as a prognostic biomarker of CV events. BET inhibition with apabetalone lowers ALP, and may thus be a promising therapeutic strategy.

  • Educational information

    • To summarise the epidemiology and pathophysiology of patients at high cardiovascular risk with diabetes
    • To understand the origin of the high residual cardiovascular risk in patients with diabetes and kidney disease
    • To review how BET inhibition affects gene expression via epigenetic mechanisms, as a novel strategy to improve outcomes in CVD and CKD
    • To update and review current clinical research programmes evaluating the role of epigenetic regulation of gene expression in CVD management
  • Disclosures

    Kamyar Kalantar-Zade, MD UC Irvine School of Medicine Irvine, Ca, USA

  • Funding

    The symposium was supported by an unrestricted educational grant from Resverlogix Corp

    The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.

Facebook Comments

Register

We’re glad to see you’re enjoying PACE-CME…
but how about a more personalized experience?

Register for free